Dry eye disease: An immune-mediated ocular surface disorder

Archives of Ophthalmology

Volumn 130, Issue 1, 2012, Pages 90-100

  Stevenson, William ^a   Chauhan, Sunil K ^a   Dana, Reza ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; COLLAGENASE 3; CORTICOSTEROID; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; CYCLOSPORIN A; DOXYCYCLINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MINOCYCLINE; OMEGA 3 FATTY ACID; RANTES; STROMELYSIN; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

ANTIGEN PRESENTING CELL; CATARACT; CLINICAL TRIAL (TOPIC); CORNEA EPITHELIUM; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DRY EYE; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; INTRAOCULAR HYPERTENSION; LYMPHANGIOGENESIS; NATURAL KILLER CELL; NEUROPATHY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH17 CELL;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN-PRESENTING CELLS; CONJUNCTIVA; EPITHELIAL CELLS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; KERATOCONJUNCTIVITIS SICCA; KILLER CELLS, NATURAL; LYMPHANGIOGENESIS; T-LYMPHOCYTES, REGULATORY;

EID: 84855586077     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.364     Document Type: Review

References (132)

1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75-92.
2. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):93-107.
3. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136(2):318-326. (Pubitemid 36904081)
4. Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. Arch Ophthalmol. 2009;127(6):763-768.
5. Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA. 2001;286(17):2114-2119. (Pubitemid 34041596)
6. Miljanović B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143(3):409-415.
7. Li M, Gong L, Sun X, Chapin WJ. Anxiety and depression in patients with dry eye syndrome. Curr Eye Res. 2011;36(1):1-7.
8. Gipson IK. The ocular surface: the challenge to enable and protect vision: the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2007;48(10):4391- 4398. (Pubitemid 351260950)
9. Research in dry eye: report of the Research Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):179-193.
10. Luo L, Li DQ, Corrales RM, Pflugfelder SC. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens. 2005;31(5):186-193. (Pubitemid 43197004)
11. De Paiva CS, Pangelinan SB, Chang E, et al. Essential role for c-Jun N-terminal kinase 2 in corneal epithelial response to desiccating stress. Arch Ophthalmol. 2009;127(12):1625-1631.
12. Li DQ, Luo L, Chen Z, Kim HS, Song XJ, Pflugfelder SC. JNK and ERK MAP kinases mediate induction of IL-1β, TNF-α and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res. 2006;82(4):588-596. (Pubitemid 43122089)
13. El Annan J, Chauhan SK, Ecoiffier T, Zhang Q, Saban DR, Dana R. Characterization of effector T cells in dry eye disease. Invest Ophthalmol Vis Sci. 2009;50(8):3802-3807.
14. De Paiva CS, Chotikavanich S, Pangelinan SB, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol. 2009;2(3):243-253.
15. Fabiani C, Barabino S, Rashid S, Dana MR. Corneal epithelial proliferation and thickness in a mouse model of dry eye. Exp Eye Res. 2009;89(2):166-171.
16. Beardsley RM, De Paiva CS, Power DF, Pflugfelder SC. Desiccating stress decreases apical corneal epithelial cell size - modulation by the metalloproteinase inhibitor doxycycline. Cornea. 2008;27(8):935-940.
17. Chen YT, Nikulina K, Lazarev S, et al. Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjögren's syndrome. Am J Pathol. 2010;177(3):1333-1343.
18. De Paiva CS, Villarreal AL, Corrales RM, et al. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-γ. Invest Ophthalmol Vis Sci. 2007;48(6):2553-2560. (Pubitemid 351261205)
19. Luo L, Li DQ, Pflugfelder SC. Hyperosmolarity-induced apoptosis in human corneal epithelial cells is mediated by cytochrome c and MAPK pathways. Cornea. 2007;26(4):452-460. (Pubitemid 46684387)
20. Yeh S, Song XJ, Farley W, Li DQ, Stern ME, Pflugfelder SC. Apoptosis of ocular surface cells in experimentally induced dry eye. Invest Ophthalmol Vis Sci. 2003;44(1):124-129. (Pubitemid 36134264)
21. Corrales RM, Stern ME, De Paiva CS, Welch J, Li DQ, Pflugfelder SC. Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium. Invest Ophthalmol Vis Sci. 2006;47(8):3293-3302. (Pubitemid 351639689)
22. Chen L, Cursiefen C, Barabino S, Zhang Q, Dana MR. Novel expression and characterization of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1) by conjunctival cells. Invest Ophthalmol Vis Sci. 2005;46(12):4536-4540. (Pubitemid 44264550)
23. Goyal S, Chauhan SK, El Annan J, Nallasamy N, Zhang Q, Dana R. Evidence of corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity? Arch Ophthalmol. 2010;128(7):819-824.
24. Chauhan SK, Jin Y, Goyal S, et al. A novel prolymphangiogenic function for Th17/IL17 [published online September 8, 2011]. Blood. doi:10.1182/blood- 2011-01-332049.
25. Skobe M, Dana R. Blocking the path of lymphatic vessels. Nat Med. 2009;15(9):993-994.
26. Müller LJ, Marfurt CF, Kruse F, Tervo TM. Corneal nerves: structure, contents and function. Exp Eye Res. 2003;76(5):521-542. (Pubitemid 36411929)
27. Müller LJ, Pels L, Vrensen GF. Ultrastructural organization of human corneal nerves. Invest Ophthalmol Vis Sci. 1996;37(4):476-488. (Pubitemid 26077668)
28. Tuominen IS, Konttinen YT, Vesaluoma MH, Moilanen JA, Helintö M, Tervo TM. Corneal innervation and morphology in primary Sjögren's syndrome. Invest Ophthalmol Vis Sci. 2003;44(6):2545-2549. (Pubitemid 36618413)
29. Benítez del Castillo JM, Wasfy MA, Fernandez C, Garcia-Sanchez J. An in vivo confocal masked study on corneal epithelium and subbasal nerves in patients with dry eye. Invest Ophthalmol Vis Sci. 2004;45(9):3030-3035.
30. Benítez-Del-Castillo JM, Acosta MC, Wassfi MA, et al. Relation between corneal innervation with confocal microscopy and corneal sensitivity with noncontact esthesiometry in patients with dry eye. Invest Ophthalmol Vis Sci. 2007;48(1):173-181. (Pubitemid 47251400)
31. Hoşal BM, Ornek N, Zilelioǧlu G, Elhan AH. Morphology of corneal nerves and corneal sensation in dry eye: a preliminary study. Eye (Lond). 2005;19(12):1276-1279. (Pubitemid 43148501)
32. Erdélyi B, Kraak R, Zhivov A, Guthoff R, Németh J. In vivo confocal laser scanning microscopy of the cornea in dry eye. Graefes Arch Clin Exp Ophthalmol. 2007;245(1):39-44. (Pubitemid 46766728)
33. Villani E, Galimberti D, Viola F, Mapelli C, Ratiglia R. The cornea in Sjogren's syndrome: an in vivo confocal study. Invest Ophthalmol Vis Sci. 2007;48(5):2017-2022. (Pubitemid 351261269)
34. Lee HK, Ryu IH, Seo KY, Hong S, Kim HC, Kim EK. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Ophthalmology. 2006;113(2):198-205. (Pubitemid 43170768)
35. Dastjerdi MH, Dana R. Corneal nerve alterations in dry eye-associated ocular surface disease. Int Ophthalmol Clin. 2009;49(1):11-20.
36. Cannon JG. Inflammatory cytokines in nonpathological states. News Physiol Sci. 2000;15:298-303.
37. Tishler M, Yaron I, Geyer O, Shirazi I, Naftaliev E, Yaron M. Elevated tear interleukin-6 levels in patients with Sjögren syndrome. Ophthalmology. 1998;105(12):2327-2329. (Pubitemid 30191679)
38. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and antiinflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42(10):2283-2292. (Pubitemid 32848857)
39. Yoon KC, Jeong IY, Park YG, Yang SY. Interleukin-6 and tumor necrosis factor-α levels in tears of patients with dry eye syndrome. Cornea. 2007;26(4):431-437.
40. Lam H, Bleiden L, de Paiva CS, Farley W, Stern ME, Pflugfelder SC. Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol. 2009;147(2):198-205, e1.
41. Massingale ML, Li X, Vallabhajosyula M, Chen D, Wei Y, Asbell PA. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea. 2009;28(9):1023-1027.
42. Enríquez-de-Salamanca A, Castellanos E, Stern ME, et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol Vis. 2010;16:862-873.
43. Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999;19(3):201-211. (Pubitemid 29500267)
44. Corrales RM, Villarreal A, Farley W, Stern ME, Li DQ, Pflugfelder SC. Strain-related cytokine profiles on the murine ocular surface in response to desiccating stress. Cornea. 2007;26(5):579-584. (Pubitemid 47164717)
45. Rashid S, Jin Y, Ecoiffier T, Barabino S, Schaumberg DA, Dana MR. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol. 2008;126(2):219-225. (Pubitemid 351240851)
46. Zhu L, Shen J, Zhang C, et al. Inflammatory cytokine expression on the ocular surface in the Botulium toxin B induced murine dry eye model. Mol Vis. 2009;15:250-258.
47. Yoon KC, Park CS, You IC, et al. Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Invest Ophthalmol Vis Sci. 2010;51(2):643-650.
48. Yoon KC, De Paiva CS, Qi H, et al. Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stress. Invest Ophthalmol Vis Sci. 2007;48(6):2561-2569. (Pubitemid 351261206)
49. El Annan J, Goyal S, Zhang Q, Freeman GJ, Sharpe AH, Dana R. Regulation of T-cell chemotaxis by programmed death-ligand 1 (PD-L1) in dry eye-associated corneal inflammation. Invest Ophthalmol Vis Sci. 2010;51(7):3418-3423.
50. Törnwall J, Lane TE, Fox RI, Fox HS. T cell attractant chemokine expression initiates lacrimal gland destruction in nonobese diabetic mice. Lab Invest. 1999;79(12):1719-1726. (Pubitemid 30013935)
51. Gulati A, Sacchetti M, Bonini S, Dana R. Chemokine receptor CCR5 expression in conjunctival epithelium of patients with dry eye syndrome. Arch Ophthalmol. 2006;124(5):710-716.
52. Goyal S, Chauhan SK, Zhang Q, Dana R. Amelioration of murine dry eye disease by topical antagonist to chemokine receptor 2. Arch Ophthalmol. 2009;127(7):882-887.
53. Li DQ, Chen Z, Song XJ, Luo L, Pflugfelder SC. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2004;45(12):4302-4311. (Pubitemid 39564654)
54. Chotikavanich S, de Paiva CS, Li Q, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci. 2009;50(7):3203-3209.
55. Acera A, Rocha G, Vecino E, Lema I, Durán JA. Inflammatory markers in the tears of patients with ocular surface disease. Ophthalmic Res. 2008;40(6):315-321.
56. Pflugfelder SC, Farley W, Luo L, et al. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. Am J Pathol. 2005;166(1):61-71. (Pubitemid 40051660)
57. Smith VA, Rishmawi H, Hussein H, Easty DL. Tear film MMP accumulation and corneal disease. Br J Ophthalmol. 2001;85(2):147-153. (Pubitemid 32146751)
58. De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res. 2006;83(3):526-535. (Pubitemid 43902774)
59. Brignole F, Pisella PJ, Goldschild M, De Saint Jean M, Goguel A, Baudouin C. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci. 2000;41(6):1356- 1363. (Pubitemid 30261857)
60. Baudouin C, Brignole F, Pisella PJ, De Saint Jean M, Goguel A. Flow cytometric analysis of the inflammatory marker HLA DR in dry eye syndrome: results from 12 months of randomized treatment with topical cyclosporin A. Adv Exp Med Biol. 2002;506(pt B):761-769.
61. Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. Invest Ophthalmol Vis Sci. 2002;43(8):2609-2614. (Pubitemid 34809449)
62. Ogawa Y, Kuwana M, Yamazaki K, et al. Periductal area as the primary site for T-cell activation in lacrimal gland chronic graft-versus-host disease. Invest Ophthalmol Vis Sci. 2003;44(5):1888-1896. (Pubitemid 36520277)
63. Tsubota K, Fujihara T, Saito K, Takeuchi T. Conjunctival epithelium expression of HLA-DR in dry eye patients. Ophthalmologica. 1999;213(1):16-19. (Pubitemid 28561779)
64. Jones DT, Monroy D, Ji Z, Atherton SS, Pflugfelder SC. Sjögren's syndrome: cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium. Invest Ophthalmol Vis Sci. 1994;35(9):3493-3504. (Pubitemid 24337956)
65. Tsubota K, Fujita H, Tsuzaka K, Takeuchi T. Quantitative analysis of lacrimal gland function, apoptotic figures, Fas and Fas ligand expression of lacrimal glands in dry eye patients. Exp Eye Res. 2003;76(2):233-240. (Pubitemid 36263349)
66. Gao J, Morgan G, Tieu D, et al. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice. Exp Eye Res. 2004;78(4):823-835. (Pubitemid 38252959)
67. Aronni S, Cortes M, Sacchetti M, et al. Upregulation of ICAM-1 expression in the conjunctiva of patients with chronic graft-versus-host disease. Eur J Ophthalmol. 2006;16(1):17-23.
68. Saito I, Terauchi K, Shimuta M, et al. Expression of cell adhesion molecules in the salivary and lacrimal glands of Sjogren's syndrome. J Clin Lab Anal. 1993;7(3):180-187. (Pubitemid 23149068)
69. 1 (VLA-4) in dry eye disease. Arch Ophthalmol. 2008;126(12):1695-1699.
70. Sallusto F, Lanzavecchia A. The instructive role of dendritic cells on T-cell responses. Arthritis Res. 2002;4(suppl 3):S127-S132.
71. Hamrah P, Liu Y, Zhang Q, Dana MR. Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation. Arch Ophthalmol. 2003;121(8):1132-1140. (Pubitemid 36962167)
72. Klareskog L, Forsum U, Tjernlund UM, Rask L, Peterson PA. Expression of Ia antigen-like molecules on cells in the corneal epithelium. Invest Ophthalmol Vis Sci. 1979;18(3):310-313. (Pubitemid 9111234)
73. Hamrah P, Liu Y, Zhang Q, Dana MR. The corneal stroma is endowed with a significant number of resident dendritic cells. Invest Ophthalmol Vis Sci. 2003;44(2):581-589. (Pubitemid 36159702)
74. Brissette-Storkus CS, Reynolds SM, Lepisto AJ, Hendricks RL. Identification of a novel macrophage population in the normal mouse corneal stroma. Invest Ophthalmol Vis Sci. 2002;43(7):2264-2271. (Pubitemid 34700657)
75. Hattori T, Chauhan SK, Lee H, et al. Characterization of Langerin-expressing dendritic cell subsetsin the normal cornea. Invest Ophthalmol Vis Sci. 2011;52(7):4598-4604.
76. Lin H, Li W, Dong N, et al. Changes in corneal epithelial layer inflammatory cells in aqueous tear-deficient dry eye. Invest Ophthalmol Vis Sci. 2010;51(1):122-128.
77. Zheng X, de Paiva CS, Li DQ, Farley WJ, Pflugfelder SC. Desiccating stress promotion of Th17 differentiation by ocular surface tissues through a dendritic cell-mediated pathway. Invest Ophthalmol Vis Sci. 2010;51(6):3083- 3091.
78. Chauhan SK, El Annan J, Ecoiffier T, et al. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol. 2009;182(3):1247-1252.
79. Chauhan SK, Dana R. Role of Th17 cells in the immunopathogenesis of dry eye disease. Mucosal Immunol. 2009;2(4):375-376.
80. Bernard F, Romano A, Granel B. Regulatory T cells and systemic autoimmune diseases: systemic lupus erythematosus, rheumatoid arthritis, primary Sjögren's syndrome. Rev Med Interne. 2010;31(2):116-127.
81. Niederkorn JY, Stern ME, Pflugfelder SC, et al. Desiccating stress induces T cell-mediated Sjögren's syndrome-like lacrimal keratoconjunctivitis. J Immunol. 2006;176(7):3950-3957. (Pubitemid 44264372)
82. + regulatory T cells maintain a normal phenotype and suppress immune-mediated ocular surface inflammation. Invest Ophthalmol Vis Sci. 2008;49(12):5434-5440.
83. Pedersen BK, Oxholm P. Impaired release of natural killer cytotoxic factor in patients with primary Sjögren's syndrome. Clin Exp Immunol. 1988;72(2):299-302.
84. Struyf NJ, Snoeck HW, Bridts CH, De Clerck LS, Stevens WJ. Natural killer cell activity in Sjögren's syndrome and systemic lupus erythematosus: stimulation with interferons and interleukin-2 and correlation with immune complexes. Ann Rheum Dis. 1990;49(9):690-693. (Pubitemid 20279120)
85. Izumi Y, Ida H, Huang M, et al. Characterization of peripheral natural killer cells in primary Sjögren's syndrome: impaired NK cell activity and low NK cell number. J Lab Clin Med. 2006;147(5):242-249. (Pubitemid 43668484)
86. Szodoray P, Gal I, Barath S, et al. Immunological alterations in newly diagnosed primary Sjögren's syndrome characterized by skewed peripheral T-cell subsets and inflammatory cytokines. Scand J Rheumatol. 2008;37(3):205-212. (Pubitemid 351874010)
87. Szodoray P, Papp G, Horvath IF, et al. Cells with regulatory function of the innate and adaptive immune system in primary Sjögren's syndrome. Clin Exp Immunol. 2009;157(3):343-349.
88. Barabino S, Montaldo E, Solignani F, Valente C, Mingari MC, Rolando M. Immune response in the conjunctival epithelium of patients with dry eye. Exp Eye Res. 2010;91(4):524-529.
89. Chen Y, Chauhan SK, Saban DR, Sadrai Z, Okanobo A, Dana R. Interferon-γ-secreting NK cells promote induction of dry eye disease. J Leukoc Biol. 2011;89(6):965-972.
90. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):163-178.
91. Nichols KK. Patient-reported symptoms in dry dye disease. Ocul Surf. 2006;4(3):137-145. (Pubitemid 351902292)
92. Turner K, Pflugfelder SC, Ji Z, Feuer WJ, Stern M, Reis BL. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea. 2000;19(4):492-496. (Pubitemid 30460887)
93. Brignole F, Pisella PJ, De Saint Jean M, Goldschild M, Goguel A, Baudouin C. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci. 2001;42(1):90-95. (Pubitemid 32059414)
94. Kojima T, Matsumoto Y, Dogru M, Tsubota K. The application of in vivo laser scanning confocal microscopy as a tool of conjunctival in vivo cytology in the diagnosis of dry eye ocular surface disease. Mol Vis. 2010;16:2457-2464.
95. Villani E, Beretta S, De Capitani M, Galimberti D, Viola F, Ratiglia R. In vivo confocal microscopy of meibomian glands in Sjögren's syndrome. Invest Ophthalmol Vis Sci. 2011;52(2):933-939.
96. Versura P, Profazio V, Fresina M, Campos EC. A novel scraping cytology score system (SCSS) grades inflammation in dry eye patients. Curr Eye Res. 2009;34(5):340-346.
97. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47(2-3):119-125. (Pubitemid 30394535)
98. Yoshida A, Fujihara T, Nakata K. Cyclosporin A increases tear fluid secretion via release of sensory neurotransmitters and muscarinic pathway in mice. Exp Eye Res. 1999;68(5):541-546. (Pubitemid 29244140)
99. Stevenson D, Tauber J, Reis BL; Cyclosporin A Phase 2 Study Group. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. Ophthalmology. 2000;107(5):967-974.
100. Sall K, Stevenson OD, Mundorf TK, Reis BL; CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000;107(4):631-639. (Pubitemid 30191329)
101. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120(3):330-337. (Pubitemid 34250055)
102. Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea. 2009;28(10):1091-1096.
103. Solomon A, Rosenblatt M, Li D, et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Am J Ophthalmol. 2000;130(5):688.
104. Hashimoto S, Gon Y, Matsumoto K, Takeshita I, Maruoka S, Horie T. Inhalant corticosteroids inhibit hyperosmolarity-induced, and cooling and rewarming-induced interleukin-8 and RANTES production by human bronchial epithelial cells. Am J Respir Crit Care Med. 2000;162(3, pt 1):1075-1080.
105. Liden J, Rafter I, Truss M, Gustafsson JA, Okret S. Glucocorticoid effects on NF-kappaB binding in the transcription of the ICAM-1 gene. Biochem Biophys Res Commun. 2000;273(3):1008-1014. (Pubitemid 30481070)
106. Aksoy MO, Li X, Borenstein M, Yi Y, Kelsen SG. Effects of topical corticosteroids on inflammatory mediator-induced eicosanoid release by human airway epithelial cells. J Allergy Clin Immunol. 1999;103(6):1081-1091. (Pubitemid 29343074)
107. Brunner T, Arnold D, Wasem C, Herren S, Frutschi C. Regulation of cell death and survival in intestinal intraepithelial lymphocytes. Cell Death Differ. 2001;8(7):706-714. (Pubitemid 32685168)
108. Dursun D, Kim MC, Solomon A, Pflugfelder SC. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. Am J Ophthalmol. 2001;132(1):8-13. (Pubitemid 32600883)
109. De Paiva CS, Corrales RM, Villarreal AL, et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Invest Ophthalmol Vis Sci. 2006;47(7):2847-2856. (Pubitemid 351639757)
110. Lekhanont K, Leyngold IM, Suwan-Apichon O, Rangsin R, Chuck RS. Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model. Cornea. 2007;26(1):84-89. (Pubitemid 46041569)
111. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology. 1999;106(4):811-816. (Pubitemid 30194327)
112. Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol. 2003;136(4):593-602. (Pubitemid 37153173)
113. Pflugfelder SC, Maskin SL, Anderson B, et al.Arandomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138(3):444-457. (Pubitemid 39208573)
114. Cordero-Coma M, Anzaar F, Sobrin L, Foster CS. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation. Ocul Immunol Inflamm. 2007;15(2):99-104. (Pubitemid 46897685)
115. Hong S, Kim T, Chung SH, Kim EK, Seo KY. Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren's syndrome. J Ocul Pharmacol Ther. 2007;23(1):78-82. (Pubitemid 46449305)
116. Nikodemova M, Watters JJ, Jackson SJ, Yang SK, Duncan ID. Minocycline downregulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)α/βII. J Biol Chem. 2007;282(20):15208-15216. (Pubitemid 47093379)
117. Shafaa MW, El Shazly LH, El Shazly AH, El gohary AA, El hossary GG. Efficacy of topically applied liposome-bound tetracycline in the treatment of dry eye model. Vet Ophthalmol. 2011;14(1):18-25.
118. Voils SA, Evans ME, Lane MT, Schosser RH, Rapp RP. Use of macrolides and tetracyclines for chronic inflammatory diseases. Ann Pharmacother. 2005;39(1):86-94. (Pubitemid 40052383)
119. Stone DU, Chodosh J. Oral tetracyclines for ocular rosacea: an evidence-based review of the literature. Cornea. 2004;23(1):106-109. (Pubitemid 38031886)
120. Gilbard JP. Dry eye, blepharitis and chronic eye irritation: divide and conquer. J Ophthalmic Nurs Technol. 1999;18(3):109-115.
121. Bartholomew RS, Reid BJ, Cheesbrough MJ, Macdonald M, Galloway NR. Oxytetracycline in the treatment of ocular rosacea: a double-blind trial. Br J Ophthalmol. 1982;66(6):386-388. (Pubitemid 12081691)
122. Seal DV, Wright P, Ficker L, Hagan K, Troski M, Menday P. Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea. Br J Ophthalmol. 1995;79(1):42-45.
123. Rosenberg ES, Asbell PA. Essential fatty acids in the treatment of dry eye. Ocul Surf. 2010;8(1):18-28.
124. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000;71(1)(suppl):343S-348S. (Pubitemid 30046139)
125. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 1989;320(5):265-271. (Pubitemid 19045549)
126. Miljanović B, Trivedi KA, Dana MR, Gilbard JP, Buring JE, Schaumberg DA. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. Am J Clin Nutr. 2005;82(4):887-893. (Pubitemid 43779705)
127. Barabino S, Rolando M, Camicione P, et al. Systemic linoleic and γ-linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea. 2003;22(2):97-101. (Pubitemid 36701907)
128. Aragona P, Bucolo C, Spinella R, Giuffrida S, Ferreri G. Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjögren's syndrome patients. Invest Ophthalmol Vis Sci. 2005;46(12):4474-4479. (Pubitemid 44264541)
129. Wojtowicz JC, Butovich I, Uchiyama E, Aronowicz J, Agee S, McCulley JP. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye. Cornea. 2011;30(3):308-314.
130. Oxholm P, Manthorpe R, Prause JU, Horrobin D. Patients with primary Sjögren's syndrome treated for two months with evening primrose oil. Scand J Rheumatol. 1986;15(2):103-108. (Pubitemid 16048707)
131. Theander E, Horrobin DF, Jacobsson LT, Manthorpe R. Gammalinolenic acid treatment of fatigue associated with primary Sjögren's syndrome. Scand J Rheumatol. 2002;31(2):72-79. (Pubitemid 34518084)
132. Li N, He J, Schwartz CE, Gjorstrup P, Bazan HE. Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model. J Ocul Pharmacol Ther. 2010;26(5):431-439.